A Novel Replication-Competent Vaccinia Vector MVTT Is Superior to MVA for Inducing High Levels of Neutralizing Antibody via Mucosal Vaccination
Figure 1
The schematic representation of MVTT-S construction and the expression of the S-glycoprotein in cells infected with MVTT-S.
(A) The S gene of SARS-CoV was introduced, together with GFP gene, each under a separate promoter, into the genome of MVTT. The restriction enzymes Bam HI and Xho I were used for constructing MVTT-S. The insertion region corresponds to the Del III region of MVA. (B) The S-glycoprotein was detected on Vero cells infected with MVTT-S (left image) using a rabbit anti-S specific antibody in an immunohistochemical staining assay. No S-glycoprotein expression was detected on Vero cells infected with the wild-type VTT (right image). (C) The comparable level of S-glycoprotein expression was detected in CEF cells infected with 1×106 PFU of either MVTT-S (lane 2) or MVA-S (lane 3) using the Western blot assay. Uninfected CEF was included as a negative control (lane 1).